Evidence map›Paper›PMID 41340149›Full record

ReviewClinical epigenetics2025

Histone deacetylases in Duchenne muscular dystrophy: a role in the mechanism of disease and a target for inhibition.

Mariarita Bertoldi, Emilio Albamonte, Luca Bello, Adele D'amico, Riccardo Masson, Vincenzo Nigro, Marika Pane, Chiara Panicucci, Maria Sframeli, Federica Ricci

Abstract readReview
In one paragraph

Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariarita BertoldiSection of Biochemistry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. mita.bertoldi@univr.it.
Emilio AlbamonteThe NEMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, 20162, Milan, Italy.
Luca BelloDepartment of Neurosciences DNS, University of Padova, Padua, Italy.
Adele D'amicoUnit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital IRCCS, 00163, Rome, Italy.
Riccardo MassonDepartment of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', 20133, Milan, Italy.
Vincenzo NigroDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi de Crecchio 7, 80138, Naples, Italy.
Marika PaneDepartment of Life Science and Public Health, Pediatric Neurology, Catholic University of Sacred Heart, Rome, Italy.
Chiara PanicucciCentre of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Maria SframeliDepartment of Clinical and Experimental Medicine, University of Messina, 98122, Messina, Italy.
Federica RicciNeuromuscular Unit, Department of Neurosciences RLM, University of Torino, 10126, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activity of histone deacetylases (HDACs) is a pathological phenomenon in several diseases, including Duchenne muscular dystrophy (DMD). In DMD, the upregulation of HDACs is driven by the disassembly of the dystrophin-associated protein complex (DAPC), which, under normal physiological conditions, provides mechanical stability to muscle fibres and acts as a signalling hub anchoring signalling proteins and molecules to their functional sites. In dystrophic muscle, DAPC disassembly causes delocalisation of signalling proteins and, therefore, disrupts signalling pathways. Displacement of epigenetic signalling molecules leads to the uncontrolled activity of HDACs and excessive removal of acetyl groups from histone proteins. Consequently, chromatin becomes tightly bound, preventing the expression of genes involved in muscle homeostasis. The pathological consequences of increased HDAC activity extend beyond muscle fibres, affecting several cell types, translating into a chronically activated immune system, promoting fibrotic and adipose tissue formation and impairing muscle regeneration. Here, we review the current evidence implicating HDACs as a key driver in DMD disease development and progression. We describe the mechanism of HDAC overactivity and the downstream consequences that contribute to the pathogenesis of the disease by disrupting muscle repair and regeneration. Finally, we highlight HDACs as targets for inhibition, offering a novel therapeutic strategy to counteract the multiple pathological events in DMD.

Indexed as

Histone Deacetylase InhibitorsHistone DeacetylasesMuscular Dystrophy, DuchenneAnimalsDystrophinEpigenesis, GeneticHumansMuscle, SkeletalSignal TransductionDystrophinHistone Deacetylase InhibitorsHistone Deacetylases

Identifiers

PMID41340149
PMCPMC12781792

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.